T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs

International Journal of Neuropsychopharmacology

Volumn 16, Issue 5, 2013, Pages 967-974

  Lim, Shinn Won ^a   Kim, Seonwoo ^a   Carroll, Bernard J ^b   Kim, Doh Kwan ^a,c  

^a Samsung Medical Center   (South Korea)

^b Pacific Behavioral Research Foundation   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antidepressant; biomarker; CREB; depression; peripheral lymphocyte

Indexed keywords

BIOLOGICAL MARKER; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FLUOXETINE; LORAZEPAM; PAROXETINE; SERTRALINE;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNOREACTIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTION; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REMISSION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIGENS, CD3; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; SEROTONIN UPTAKE INHIBITORS; T-LYMPHOCYTES;

EID: 84877991719     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001125     Document Type: Article

References (35)

1. Barkan T, Gurwitz D, Levy G, Weizman A, et al. (2004). Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. European Neuropsychopharmacology 14, 237-243.
2. Bianchi M, Moser C, Lazzarini C, Vecchiato E, et al. (2002). Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Experimental Brain Research 143, 191-197.
3. Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 69, 89-95.
4. Blendy JA (2006). The role of CREB in depression and antidepressant treatment. Biological Psychiatry 59, 1144-1150.
5. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, et al. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biological Psychiatry 50, 260-265.
6. Cohen J (1992). A power primer. Psychological Bulletin 112, 155-159.
7. Colligan RC, Osborne D, Swenson WM, Offord KP (1984). The MMPI: development of contemporary norms. Journal of Clinical Psychology 40, 100-107.
8. Dowlatshahi D, MacQueen GM, Wang JF, Young LT (1998). Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352, 1754-1755.
9. D'Sa C, Duman RS (2002). Antidepressants and neuroplasticity. Bipolar Disorders 4, 183-194.
10. Duman RS, Malberg J, Thome J (1999). Neural plasticity to stress and antidepressant treatment. Biological Psychiatry 46, 1181-1191.
11. Fujioka T, Fujioka A, Duman RS (2004). Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. Journal of Neuroscience 24, 319-328.
12. Gonzalez GA, Montminy MR (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680.
13. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
14. Imaki J, Yoshida K, Yamashita K (1994). A developmental study of cyclic AMP-response element binding protein (CREB) by in situ hybridization histochemistry and immuno-cytochemistry in the rat neocortex. Brain Research 651, 269-274.
15. Itoh T, Tokumura M, Abe K (2004). Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. European Journal of Pharmacology 498, 135-142.
16. Karasu TB, Gelenberg A, Merriam A, Wang P (2000) Treatment of patients with major depressive disorder. In: McIntyre JS, Charles SC (Eds.), American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. Compendium 2000 (pp. 413-495) Arlington, VA: American Psychiatric Association.
17. Kim H, Lim SW, Kim S, Kim JW, et al. (2006). Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. Journal of the American Medical Association 296, 1609-1618.
18. Koch JM, Hinze-Selch D, Stingele K, Huchzermeier C, et al. (2009). Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychotherapy and Psychosomatics 78, 187-192.
19. Koch JM, Kell S, Hinze-Selch D, Aldenhoff JB (2002). Changes in CREB-phosphorylation during recovery from major depression. Journal of Psychiatric Research 36, 369-375.
20. Légrádi G, Holzer D, Kapcala LP, Lechan RM (1997). Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus. Neuroendocrinology 66, 86-97.
21. Leuner K, Pantel J, Frey C, Schindowski K, et al. (2007). Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. Journal of Neural Transmission. Supplementum 207-215.
22. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, et al. (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica Supplementum 334, 1-100.
23. Montminy MR, Bilezikjian LM (1987). Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328, 175-178.
24. Nierenberg AA, Amsterdam JD (1990). Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry 51 (Suppl.), 39-47; discussion 48-50.
25. Papakostas GI, Fava M (2008). Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues in Clinical Neuroscience 10, 439-451.
26. Pietraszek MH, Urano T, Sumiyoshi K, Takada Y, et al. (1992). Diurnal variations of whole blood serotonin content in patients with depression and neurosis. Journal of Neurology, Neurosurgery and Psychiatry 55, 336.
27. Ren X, Dwivedi Y, Mondal AC, Pandey GN (2011). Cyclic-AMP response element binding protein (CREB) in the neutrophils of depressed patients. Psychiatry Research 185, 108-112.
28. Stieler JT, Lederer C, Bruckner MK, Wolf H, et al. (2001). Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport 12, 3969-3972.
29. Thome J, Sakai N, Shin K, Steffen C, et al. (2000). cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. Journal of Neuroscience 20, 4030-4036.
30. Tiraboschi E, Tardito D, Kasahara J, Moraschi S, et al. (2004). Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 29, 1831-1840.
31. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40.
32. West AE, Griffith EC, Greenberg ME (2002). Regulation of transcription factors by neuronal activity. Nature Reviews Neuroscience 3, 921-931.
33. Yamada S, Yamamoto M, Ozawa H, Riederer P, et al. (2003). Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. Journal of Neural Transmission 110, 671-680.
34. Yamamoto KK, Gonzalez GA, Biggs 3rd WH, Montminy MR (1988). Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334, 494-498.
35. Zhang HX, Zhao JP, Lv LX, Li WQ, et al. (2008). Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neuroscience Letters 438, 1-5.